Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update
03 mars 2022 16h15 HE
|
Histogen Inc
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Reports Third Quarter 2021 Earnings and Provides Business Update
10 nov. 2021 16h05 HE
|
Histogen Inc
Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee On-Going with Top-Line Data Expected in the Second Half of 2022 IND Filing for HST 004 for Spinal Disc Repair Anticipated in the...
Histogen Announces CEO Transition
08 nov. 2021 16h05 HE
|
Histogen Inc
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, Asthma, and Immunology Conference
02 nov. 2021 08h00 HE
|
Histogen Inc
Phase 1 Study in Mild COVID-19 Patients Demonstrated a Favorable Safety and Tolerability Profile and Statistically Significant Clinical Symptom and Biomarker Improvements Additional Analysis...
Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021
27 oct. 2021 08h00 HE
|
Histogen Inc
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
31 août 2021 16h05 HE
|
Histogen Inc
SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
16 août 2021 08h00 HE
|
Histogen Inc
Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression Emricasan Found to Have Statistically Significant Improvements in Clinically Relevant Hematological and...
Histogen Reports Second Quarter 2021 Earnings and Provides Business Update
11 août 2021 16h05 HE
|
Histogen Inc
Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates Initiated Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee HST 004...
Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference
29 juil. 2021 16h05 HE
|
Histogen Inc
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration
30 juin 2021 08h00 HE
|
Histogen Inc
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced the initiation of its Phase 1/2 clinical trial of HST 003 to evaluate the safety and efficacy of human...